Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05179824 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tempus Priority Study: A Pan-tumor Observational Study

StatusActive, Not Recruiting
PhaseNot specified
SponsorTempus AI
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv15
  2. Study Identification, Study Status, Oversight, IPDSharingv14
  3. Trial status: Recruiting to Active, Not Recruiting Study sites: 12 to 2v13 Show 1 more changeShow less
    • Study sites: 12 to 2
  4. Site details revised at 1 of 12 sitesv12
  5. 2 versions Re-verified since May 21, 2024, no change to tracked fieldsv10-v11
Show 8 earlier versionsHide 8 earlier versions
  1. Site details revised at 3 of 12 sitesv9
  2. Eligibility criteria shortened, about 16 words Site details revised at 7 of 12 sites · Study arms: 2 to 1v8 Show 2 more changesShow less
    • Site details revised at 7 of 12 sites
    • Study arms: 2 to 1

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 10 to 12v7
  4. 2 versions Re-verified since Nov 22, 2023, no change to tracked fieldsv5-v6
  5. Study sites: 8 to 10v4
  6. Study sites: 5 to 8v3
  7. Interventions: Observation (Other)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tempus AI
13 trials monitored
See all monitored trials
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Leukemia
2,566 trials monitored
See 143 trials at risk
and 12 more diseases
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.
Trial Details
NCT Number NCT05179824
Lead Sponsor Tempus AI
Conditions Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer +19 more
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov